Day One Biopharmaceuticals Key Executives
This section highlights Day One Biopharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Day One Biopharmaceuticals
(Showing 0 of )
Day One Biopharmaceuticals Earnings
This section highlights Day One Biopharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-26 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $-0.41 | $0.38 |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
$7.67
Stock Price
$776.89M
Market Cap
181
Employees
South San Francisco, CA
Location
Financial Statements
Access annual & quarterly financial statements for Day One Biopharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $131.16M | $- | $- | $- | $- |
| Cost of Revenue | $5.28M | $383.00K | $531.00K | $199.00K | $155.00K |
| Gross Profit | $125.88M | $-383.00K | $-531.00K | $-199.00K | $-155.00K |
| Gross Profit Ratio | 96.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $227.70M | $130.52M | $85.62M | $43.58M | $9.10M |
| General and Administrative Expenses | $- | $75.54M | $61.29M | $29.16M | $4.68M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $115.45M | $75.54M | $61.29M | $29.16M | $4.68M |
| Other Expenses | $- | $1 | $-18.00K | $-15.00K | $-31.00K |
| Operating Expenses | $343.15M | $206.06M | $146.91M | $72.74M | $13.78M |
| Cost and Expenses | $348.43M | $206.06M | $146.91M | $72.74M | $13.78M |
| Interest Income | $- | $17.19M | $4.75M | $4.00K | $30 |
| Interest Expense | $- | $- | $4.75M | $4.00K | $30.00K |
| Depreciation and Amortization | $- | $383.00K | $531.00K | $199.00K | $155.00K |
| EBITDA | $-217.27M | $-206.06M | $-141.65M | $-72.56M | $-43.66M |
| EBITDA Ratio | -165.65% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-217.27M | $-206.06M | $-146.91M | $-72.74M | $-13.78M |
| Operating Income Ratio | -165.65% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $128.92M | $17.15M | $4.73M | $-11.00K | $-30.06M |
| Income Before Tax | $-88.35M | $-188.92M | $-142.18M | $-72.75M | $-43.84M |
| Income Before Tax Ratio | -67.36% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-7.14M | $- | $-10.01M | $-2.31M | $-3.34M |
| Net Income | $-95.50M | $-188.92M | $-132.18M | $-70.44M | $-40.51M |
| Net Income Ratio | -72.81% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.02 | $-2.37 | $-2.02 | $-1.14 | $-0.65 |
| EPS Diluted | $-1.02 | $-2.37 | $-2.02 | $-1.14 | $-0.65 |
| Weighted Average Shares Outstanding | 93.62M | 79.77M | 65.47M | 61.95M | 61.93M |
| Weighted Average Shares Outstanding Diluted | 93.62M | 79.77M | 65.47M | 61.95M | 61.93M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.21M | $93.76M | $8.19M | $- | $560.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $2.98M | $1.59M | $707.00K | $116.00K | $280.00K | $99.00K | $92.00K | $89.00K | $180.00K | $165.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $26.23M | $92.17M | $7.49M | $-116.00K | $280.00K | $-99.00K | $-92.00K | $-89.00K | $-180.00K | $-165.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 89.80% | 98.30% | 91.40% | 0.00% | 50.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $61.82M | $33.56M | $92.11M | $40.21M | $37.35M | $33.16M | $32.18M | $27.83M | $26.02M | $22.04M | $22.56M | $15.00M | $43.58M | $9.85M | $9.91M | $12.63M | $4.17M | $2.54M | $1.44M | $961.00K |
| General and Administrative Expenses | $- | $- | $30.19M | $26.56M | $22.17M | $18.27M | $17.07M | $18.03M | $16.72M | $17.66M | $14.16M | $12.74M | $29.16M | $9.39M | $5.53M | $3.45M | $1.98M | $1.02M | $872.00K | $808.00K |
| Selling and Marketing Expenses | $- | $- | $- | $-116.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $29.73M | $28.97M | $30.19M | $26.44M | $22.17M | $18.27M | $17.07M | $18.03M | $16.72M | $17.66M | $14.16M | $12.74M | $29.16M | $9.39M | $5.53M | $3.45M | $1.98M | $1.02M | $872.00K | $808.00K |
| Other Expenses | $- | $- | $107.99M | $-10.00K | $-18.00K | $-3.00K | $-15.00K | $-4.00K | $-26.00K | $9.00K | $- | $-1.00K | $14.00K | $7.00K | $-27.00K | $-8.00K | $-26.00K | $-1.00K | $-90.00K | $-2.00K |
| Operating Expenses | $91.56M | $62.53M | $122.29M | $66.65M | $59.52M | $51.44M | $49.25M | $45.85M | $42.74M | $39.70M | $36.72M | $27.75M | $72.74M | $19.24M | $15.44M | $16.09M | $6.14M | $3.56M | $2.31M | $1.77M |
| Cost and Expenses | $94.54M | $64.12M | $123.00M | $66.77M | $59.52M | $51.44M | $49.25M | $45.85M | $42.74M | $39.70M | $36.72M | $27.75M | $72.74M | $19.24M | $15.44M | $16.09M | $6.14M | $3.56M | $2.31M | $1.77M |
| Interest Income | $- | $- | $3.96M | $- | $- | $5.29M | $3.41M | $- | $2.66M | $1.90M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $2.66M | $1.90M | $- | $2.00K | $4.00K | $6.00K | $7.00K | $7.00K | $8.00K | $9.00K | $10.00K | $3.00K |
| Depreciation and Amortization | $759.00K | $- | $408.00K | $116.00K | $103.00K | $99.00K | $92.00K | $89.00K | $180.00K | $165.00K | $133.00K | $53.00K | $5.00K | $50.00K | $49.00K | $49.00K | $49.00K | $46.00K | $46.00K | $14.00K |
| EBITDA | $-64.57M | $29.64M | $-114.49M | $-66.77M | $-59.50M | $-51.44M | $-49.25M | $-45.85M | $-42.73M | $-39.70M | $-36.59M | $-27.75M | $-21.97M | $-19.18M | $-15.39M | $-16.04M | $-35.54M | $-3.79M | $-2.35M | $-1.98M |
| EBITDA Ratio | -221.08% | 31.61% | -1396.47% | 0.00% | -11506.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-65.33M | $29.64M | $-114.81M | $-66.77M | $-59.52M | $-51.44M | $-49.25M | $-45.85M | $-42.74M | $-39.70M | $-36.72M | $-27.75M | $-121.93M | $-19.24M | $-15.44M | $-16.09M | $-6.14M | $-3.56M | $-2.31M | $-1.77M |
| Operating Income Ratio | -223.68% | 31.61% | -1401.45% | 0.00% | -10628.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $6.09M | $6.52M | $111.95M | $4.35M | $5.01M | $5.29M | $3.39M | $3.46M | $2.63M | $1.90M | $189.00K | $1.00K | $37.00K | $1.00K | $-34.00K | $-15.00K | $-29.46M | $-281.00K | $-100.00K | $-223.00K |
| Income Before Tax | $-59.24M | $36.16M | $-2.85M | $-62.41M | $-54.51M | $-46.15M | $-45.86M | $-42.39M | $-40.11M | $-37.80M | $-36.53M | $-27.75M | $-119.83M | $-19.24M | $-15.47M | $-16.10M | $-35.60M | $-3.84M | $-2.41M | $-1.99M |
| Income Before Tax Ratio | -202.82% | 38.56% | -34.85% | 0.00% | -9734.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $6.47M | $-882.00K | $1.55M | $72.72K | $10.52M | $-99.00K | $-3.41M | $-7.02M | $-5.29M | $-3.80M | $-189.00K | $-3.00K | $4.00K | $7.00K | $-27.00K | $-920.00K | $-1.24M | $-1.01M | $-639.00K | $-456.00K |
| Net Income | $-65.71M | $37.04M | $-4.41M | $-62.41M | $-54.51M | $-46.15M | $-45.86M | $-35.38M | $-34.81M | $-34.00M | $-36.53M | $-27.74M | $-119.83M | $-19.24M | $-14.28M | $-15.18M | $-34.38M | $-2.82M | $-1.76M | $-1.53M |
| Net Income Ratio | -224.99% | 39.50% | -53.80% | 0.00% | -9734.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.70 | $0.38 | $-0.05 | $-0.72 | $-0.62 | $-0.54 | $-0.61 | $-0.49 | $-0.47 | $-0.48 | $-0.60 | $-0.48 | $-1.93 | $-0.31 | $-0.23 | $-0.25 | $-0.56 | $-0.05 | $-0.03 | $-0.02 |
| EPS Diluted | $-0.70 | $0.38 | $-0.05 | $-0.72 | $-0.62 | $-0.54 | $-0.61 | $-0.49 | $-0.47 | $-0.48 | $-0.60 | $-0.48 | $-1.93 | $-0.31 | $-0.23 | $-0.25 | $-0.56 | $-0.05 | $-0.03 | $-0.02 |
| Weighted Average Shares Outstanding | 93.62M | 96.62M | 87.12M | 86.68M | 87.23M | 85.95M | 74.96M | 71.97M | 73.46M | 71.01M | 60.76M | 58.38M | 61.95M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M |
| Weighted Average Shares Outstanding Diluted | 93.62M | 96.94M | 87.12M | 86.68M | 87.23M | 85.95M | 74.96M | 71.97M | 73.46M | 71.01M | 60.76M | 58.38M | 61.95M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M | 61.93M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $124.97M | $230.78M | $85.26M | $284.31M | $43.73M |
| Short Term Investments | $406.75M | $135.56M | $257.01M | $- | $- |
| Cash and Short Term Investments | $531.72M | $366.35M | $342.27M | $284.31M | $43.73M |
| Net Receivables | $13.88M | $- | $- | $- | $- |
| Inventory | $3.32M | $- | $- | $- | $- |
| Other Current Assets | $13.41M | $8.93M | $5.61M | $5.06M | $1.34M |
| Total Current Assets | $562.33M | $375.27M | $347.87M | $289.37M | $45.07M |
| Property Plant Equipment Net | $4.71M | $560.00K | $719.00K | $284.00K | $483.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $15.63M | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $15.63M | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $121.00K | $214.00K | $469.00K | $169.00K | $107.00K |
| Total Non-Current Assets | $20.46M | $774.00K | $1.19M | $453.00K | $590.00K |
| Other Assets | $- | $- | $- | $-0 | $- |
| Total Assets | $582.79M | $376.05M | $349.06M | $289.82M | $45.66M |
| Account Payables | $3.26M | $2.58M | $260.00K | $1.74M | $202.00K |
| Short Term Debt | $10.00K | $408.00K | $810.00K | $408.00K | $198.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $1.55M | $- | $- | $6.61M | $1.57M |
| Other Current Liabilities | $68.62M | $26.52M | $15.54M | $6.50M | $1.60M |
| Total Current Liabilities | $73.45M | $29.51M | $16.61M | $8.66M | $2.00M |
| Long Term Debt | $2.59M | $- | $408.00K | $16.00K | $204.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $3.99M | $- | $- | $- | $91.96M |
| Total Non-Current Liabilities | $6.59M | $- | $408.00K | $16.00K | $92.17M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $80.04M | $29.51M | $17.02M | $8.67M | $94.16M |
| Preferred Stock | $- | $- | $- | $- | $5.70M |
| Common Stock | $10.00K | $9.00K | $7.00K | $6.00K | $2.00M |
| Retained Earnings | $-554.08M | $-458.58M | $-269.67M | $-127.49M | $-56.84M |
| Accumulated Other Comprehensive Income Loss | $84.00K | $9.00K | $-71.00K | $0 | $637 |
| Other Total Stockholders Equity | $1.06B | $805.11M | $601.77M | $408.63M | $92.60M |
| Total Stockholders Equity | $502.75M | $346.54M | $-269.67M | $-127.49M | $-54.20M |
| Total Equity | $502.75M | $346.54M | $-269.67M | $162.33M | $-48.50M |
| Total Liabilities and Stockholders Equity | $582.79M | $376.05M | $-252.65M | $-118.81M | $45.66M |
| Minority Interest | $- | $- | $- | $289.82M | $5.70M |
| Total Liabilities and Total Equity | $582.79M | $376.05M | $-252.65M | $-118.81M | $45.66M |
| Total Investments | $406.75M | $135.56M | $257.01M | $- | $- |
| Total Debt | $2.60M | $408.00K | $813.00K | $220.00K | $402.00K |
| Net Debt | $-122.37M | $-230.38M | $-84.45M | $-284.09M | $-43.33M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $124.97M | $422.76M | $239.62M | $270.39M | $230.78M | $241.18M | $189.21M | $49.27M | $85.26M | $120.86M | $388.88M | $262.73M | $284.31M | $297.16M | $310.00M | $154.87M | $43.73M | $- |
| Short Term Investments | $406.75M | $135.62M | $122.25M | $47.55M | $135.56M | $164.36M | $253.67M | $268.91M | $257.01M | $253.48M | $5.99M | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $531.72M | $558.38M | $361.87M | $317.94M | $366.35M | $405.54M | $442.88M | $318.18M | $342.27M | $374.34M | $394.86M | $262.73M | $284.31M | $297.16M | $310.00M | $154.87M | $43.73M | $27.33M |
| Net Receivables | $13.88M | $8.70M | $9.14M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $3.32M | $2.73M | $151.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $13.41M | $11.18M | $12.01M | $8.09M | $8.93M | $7.75M | $6.90M | $4.21M | $5.61M | $6.17M | $7.64M | $4.64M | $5.06M | $6.15M | $6.03M | $115.00K | $1.34M | $- |
| Total Current Assets | $562.33M | $581.00M | $383.16M | $326.03M | $375.27M | $405.54M | $449.78M | $322.39M | $347.87M | $380.51M | $402.50M | $267.37M | $289.37M | $303.31M | $316.02M | $158.75M | $45.07M | $27.33M |
| Property Plant Equipment Net | $4.71M | $3.48M | $360.00K | $444.00K | $560.00K | $655.00K | $713.00K | $688.00K | $719.00K | $899.00K | $1.06M | $246.00K | $284.00K | $335.00K | $386.00K | $435.00K | $483.00K | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $15.63M | $16.22M | $16.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $15.63M | $16.22M | $16.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $121.00K | $117.00K | $117.00K | $167.00K | $214.00K | $7.99M | $259.00K | $487.00K | $469.00K | $449.00K | $484.00K | $165.00K | $169.00K | $137.00K | $126.00K | $1.69M | $107.00K | $-27.33M |
| Total Non-Current Assets | $20.46M | $19.81M | $17.28M | $611.00K | $774.00K | $8.64M | $972.00K | $1.18M | $1.19M | $1.35M | $1.54M | $411.00K | $453.00K | $472.00K | $512.00K | $2.12M | $590.00K | $-27.33M |
| Other Assets | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $582.79M | $600.81M | $400.44M | $326.64M | $376.05M | $414.18M | $450.76M | $323.56M | $349.06M | $381.86M | $404.05M | $267.78M | $289.82M | $303.78M | $316.54M | $160.88M | $45.66M | $- |
| Account Payables | $3.26M | $3.02M | $6.44M | $4.78M | $2.58M | $3.39M | $4.57M | $4.66M | $260.00K | $3.97M | $439.00K | $701.00K | $1.74M | $683.00K | $348.00K | $686.00K | $202.00K | $- |
| Short Term Debt | $20.00K | $154.00K | $380.00K | $300.00K | $816.00K | $874.00K | $856.00K | $834.00K | $405.00K | $924.00K | $854.00K | $342.00K | $204.00K | $404.00K | $402.00K | $199.00K | $198.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $1.55M | $1.46M | $- | $- | $25.48M | $20.24M | $19.33M | $- | $- | $- | $11.77M | $- | $6.61M | $4.98M | $4.02M | $2.17M | $1.57M | $- |
| Other Current Liabilities | $68.61M | $35.11M | $86.88M | $24.76M | $26.12M | $20.21M | $19.09M | $17.36M | $15.95M | $13.37M | $11.51M | $7.13M | $6.71M | $4.96M | $3.91M | $2.18M | $1.60M | $- |
| Total Current Liabilities | $73.45M | $39.74M | $93.71M | $29.84M | $29.51M | $24.48M | $24.51M | $22.85M | $16.61M | $18.27M | $12.80M | $8.18M | $8.66M | $6.05M | $4.66M | $3.07M | $2.00M | $- |
| Long Term Debt | $2.59M | $2.54M | $- | $- | $- | $77.00K | $190.00K | $300.00K | $408.00K | $514.00K | $617.00K | $- | $16.00K | $65.00K | $112.00K | $159.00K | $204.00K | $- |
| Deferred Revenue Non-Current | $3.23M | $3.06M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $761.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $221.72M | $91.96M | $-25.32M |
| Total Non-Current Liabilities | $6.59M | $5.60M | $- | $- | $- | $77.00K | $190.00K | $300.00K | $408.00K | $514.00K | $617.00K | $872.00K | $16.00K | $65.00K | $112.00K | $221.88M | $92.17M | $-25.32M |
| Other Liabilities | $- | $- | $- | $- | $- | $793.70M | $- | $- | $- | $- | $- | $-872.00K | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $80.04M | $45.34M | $93.71M | $29.84M | $29.51M | $818.25M | $24.70M | $23.15M | $17.02M | $18.79M | $13.42M | $8.18M | $8.67M | $6.11M | $4.77M | $224.95M | $94.16M | $-25.32M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $303.78M | $- | $4.78M | $- | $30.50M |
| Common Stock | $10.00K | $10.00K | $9.00K | $9.00K | $9.00K | $9.00K | $9.00K | $7.00K | $7.00K | $7.00K | $7.00K | $6.00K | $6.00K | $6.00K | $6.00K | $2.00M | $2.00M | $- |
| Retained Earnings | $-554.08M | $-488.37M | $-525.40M | $-521.00M | $-458.58M | $-404.07M | $-357.92M | $-312.06M | $-269.67M | $-229.56M | $-191.76M | $-155.23M | $-127.49M | $-105.55M | $-86.31M | $-72.02M | $-56.84M | $- |
| Accumulated Other Comprehensive Income Loss | $84.00K | $-6.00K | $-22.00K | $-5.00K | $9.00K | $-7.00K | $-9.00K | $67.00K | $-71.00K | $-392.00K | $-3.00K | $- | $- | $-303.78M | $- | $- | $- | $-10.67M |
| Other Total Stockholders Equity | $1.06B | $1.04B | $832.15M | $817.80M | $805.11M | $793.70M | $783.98M | $612.40M | $601.77M | $593.02M | $582.39M | $414.83M | $408.63M | $707.00M | $398.06M | $-3.61M | $92.60M | $5.49M |
| Total Stockholders Equity | $502.75M | $555.46M | $306.73M | $296.81M | $346.54M | $-404.07M | $426.05M | $-312.06M | $332.04M | $363.08M | $390.63M | $259.60M | $-127.49M | $297.67M | $311.76M | $-68.85M | $-54.20M | $25.32M |
| Total Equity | $502.75M | $555.46M | $306.73M | $296.81M | $346.54M | $-404.07M | $426.05M | $-312.06M | $332.04M | $363.08M | $390.63M | $259.60M | $- | $- | $- | $- | $- | $25.32M |
| Total Liabilities and Stockholders Equity | $582.79M | $600.81M | $400.44M | $326.64M | $376.05M | $414.18M | $450.76M | $-288.91M | $349.06M | $381.86M | $404.05M | $267.78M | $-118.81M | $303.78M | $316.54M | $160.88M | $45.66M | $- |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $316.54M | $4.78M | $5.70M | $- |
| Total Liabilities and Total Equity | $582.79M | $600.81M | $400.44M | $326.64M | $376.05M | $414.18M | $450.76M | $-288.91M | $349.06M | $381.86M | $404.05M | $267.78M | $-118.81M | $303.78M | $316.54M | $160.88M | $45.66M | $- |
| Total Investments | $406.75M | $135.62M | $122.25M | $47.55M | $135.56M | $164.36M | $253.67M | $268.91M | $257.01M | $253.48M | $5.99M | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $2.60M | $2.62M | $190.00K | $300.00K | $408.00K | $514.00K | $618.00K | $717.00K | $813.00K | $976.00K | $1.04M | $171.00K | $220.00K | $267.00K | $313.00K | $358.00K | $402.00K | $- |
| Net Debt | $-122.37M | $-420.15M | $-239.43M | $-270.09M | $-230.38M | $-240.66M | $-188.59M | $-48.55M | $-84.45M | $-119.89M | $-387.83M | $-262.56M | $-284.09M | $-296.89M | $-309.68M | $-154.51M | $-43.33M | $- |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-95.50M | $-188.92M | $-142.18M | $-72.75M | $-43.84M |
| Depreciation and Amortization | $1.56M | $383.00K | $531.00K | $199.00K | $155.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $48.26M | $39.34M | $27.24M | $13.32M | $526.00K |
| Change in Working Capital | $- | $9.42M | $6.56M | $2.69M | $-357.00K |
| Accounts Receivables | $-13.88M | $- | $- | $- | $- |
| Inventory | $-3.24M | $- | $- | $- | $- |
| Accounts Payables | $686.00K | $2.32M | $-1.48M | $1.54M | $132.00K |
| Other Working Capital | $- | $7.10M | $8.05M | $1.15M | $-489.00K |
| Other Non Cash Items | $-32.44M | $-7.08M | $-2.03M | $8.00M | $30.03M |
| Net Cash Provided by Operating Activities | $-78.11M | $-146.85M | $-109.87M | $-48.54M | $-13.49M |
| Investments in Property Plant and Equipment | $-2.17M | $-224.00K | $-26.00K | $-8.00M | $-92.00K |
| Acquisitions Net | $- | $- | $255.05K | $- | $- |
| Purchases of Investments | $-658.62M | $-443.84M | $-394.21M | $- | $- |
| Sales Maturities of Investments | $393.89M | $575.44M | $139.16M | $- | $- |
| Other Investing Activities | $35.90M | $-3.00M | $-255.05K | $-8.00M | $- |
| Net Cash Used for Investing Activities | $-230.99M | $128.38M | $-255.07M | $-8.00M | $-92.00K |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $178.18M | $161.41M | $161.61M | $167.04M | $29.98M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $25.11M | $5.18M | $4.29M | $130.07M | $29.98M |
| Net Cash Used Provided by Financing Activities | $203.29M | $164.00M | $165.90M | $297.12M | $29.98M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-105.82M | $145.52M | $-199.05M | $240.58M | $16.40M |
| Cash at End of Period | $124.97M | $230.78M | $85.26M | $284.31M | $43.73M |
| Cash at Beginning of Period | $230.78M | $85.26M | $284.31M | $43.73M | $27.33M |
| Operating Cash Flow | $-78.11M | $-146.85M | $-109.87M | $-48.54M | $-13.49M |
| Capital Expenditure | $-2.17M | $-3.22M | $-26.00K | $-8.00M | $-92.00K |
| Free Cash Flow | $-80.28M | $-150.08M | $-109.90M | $-56.54M | $-13.58M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-65.71M | $37.04M | $-4.41M | $-62.41M | $-54.51M | $-46.15M | $-45.86M | $-42.39M | $-40.11M | $-37.80M | $-36.53M | $-27.75M | $-21.94M | $-19.24M | $-15.47M | $-16.10M | $-35.60M | $-3.84M | $-2.41M | $-1.99M |
| Depreciation and Amortization | $759.00K | $746.00K | $408.00K | $116.00K | $103.00K | $99.00K | $92.00K | $89.00K | $180.00K | $165.00K | $133.00K | $53.00K | $51.00K | $50.00K | $49.00K | $49.00K | $49.00K | $46.00K | $46.00K | $14.00K |
| Deferred Income Tax | $- | $- | $- | $- | $41.58M | $-45.79M | $4.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-578.00K | $270.00K | $90.00K | $218.00K |
| Stock Based Compensation | $11.04M | $11.55M | $13.03M | $12.64M | $10.81M | $9.61M | $9.48M | $9.45M | $6.83M | $8.58M | $5.63M | $6.20M | $5.10M | $5.15M | $2.54M | $538.00K | $350.00K | $60.00K | $57.00K | $59.00K |
| Change in Working Capital | $26.73M | $-52.21M | $50.74M | $1.22M | $3.80M | $-975.00K | $-879.00K | $7.47M | $-1.22M | $6.87M | $979.00K | $-71.00K | $3.64M | $1.82M | $-525.00K | $-2.24M | $-167.00K | $-121.00K | $317.00K | $-386.00K |
| Accounts Receivables | $-5.18M | $441.00K | $-9.14M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $-560.00K | $-2.55M | $-129.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $245.00K | $-3.43M | $1.66M | $2.20M | $-815.00K | $-1.17M | $-74.00K | $4.38M | $-3.71M | $3.53M | $-262.00K | $-1.04M | $1.06M | $338.00K | $-339.00K | $484.00K | $-171.00K | $148.00K | $112.00K | $43.00K |
| Other Working Capital | $32.23M | $-46.67M | $58.34M | $-989.00K | $4.62M | $199.00K | $-805.00K | $3.09M | $2.50M | $3.34M | $1.24M | $972.00K | $2.58M | $1.48M | $-186.00K | $-2.72M | $4.00K | $-269.00K | $205.00K | $-429.00K |
| Other Non Cash Items | $-2.82M | $53.62M | $-96.72M | $9.38M | $-43.15M | $46.15M | $-9.48M | $-599.00K | $-999.00K | $-1.03M | $-262.00K | $- | $-19.00K | $5.00K | $7.00K | $8.01M | $30.01M | $9.00K | $10.00K | $3.00K |
| Net Cash Provided by Operating Activities | $-30.01M | $50.75M | $-49.13M | $-49.73M | $-41.37M | $-37.06M | $-42.43M | $-25.98M | $-35.31M | $-23.21M | $-29.79M | $-21.56M | $-13.17M | $-12.22M | $-13.41M | $-9.74M | $-5.94M | $-3.58M | $-1.89M | $-2.08M |
| Investments in Property Plant and Equipment | $-1.42M | $-724.00K | $-17.13M | $- | $-8.00K | $-3.04M | $-149.00K | $-26.00K | $- | $-4.00K | $-7.00K | $-15.00K | $8.00M | $- | $- | $-8.00M | $1.00K | $- | $-5.00K | $-88.00K |
| Acquisitions Net | $- | $- | $- | $- | $-2.99M | $3.00M | $-20.42K | $11.17K | $- | $-20.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-275.22M | $-214.63M | $-121.60M | $-47.16M | $-99.14M | $-79.96M | $-104.73M | $-160.01M | $-121.37M | $-266.85M | $-5.99M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $7.00M | $202.66M | $47.78M | $136.45M | $129.53M | $171.91M | $125.15M | $148.85M | $119.16M | $20.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-55.00M | $108.00M | $89.29M | $2.99M | $-3.00M | $20.42K | $-11.17K | $-2.21K | $20.00M | $-5.99M | $- | $-8.00M | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-269.64M | $-67.70M | $17.06M | $89.29M | $30.38M | $88.92M | $20.27M | $-11.19M | $-2.21M | $-246.85M | $-6.00M | $-15.00K | $8.00M | $- | $- | $-8.00M | $1.00K | $- | $-5.00K | $-88.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $178.18M | $1.30M | $48.00K | $597.00K | $115.00K | $162.10M | $1.18M | $1.92M | $2.05M | $- | $- | $167.66M | $-615.00K | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $1.25M | $- | $- | $- | $- | $- | $- | $- | $318.00K | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.85M | $21.92M | $1.30M | $48.00K | $597.00K | $115.00K | $162.10M | $1.18M | $1.92M | $2.05M | $161.93M | $- | $318.00K | $- | $168.53M | $128.88M | $29.98M | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $1.85M | $200.09M | $1.30M | $48.00K | $597.00K | $115.00K | $162.10M | $1.18M | $1.92M | $2.05M | $161.93M | $- | $318.00K | $-615.00K | $168.53M | $128.88M | $29.98M | $- | $- | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $228.58M | $-98.12M | $-130.47M | $- | $- | $- | $- | $- | $-8.00M | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-297.80M | $183.15M | $-30.77M | $39.61M | $-10.39M | $51.97M | $139.94M | $-35.99M | $-35.60M | $-268.01M | $126.15M | $-21.58M | $-12.85M | $-12.84M | $155.13M | $111.14M | $24.04M | $-3.58M | $-1.89M | $-2.17M |
| Cash at End of Period | $124.97M | $422.76M | $239.62M | $270.39M | $230.78M | $241.18M | $189.21M | $49.27M | $85.26M | $120.86M | $388.88M | $262.73M | $284.31M | $297.16M | $310.00M | $154.87M | $43.73M | $19.69M | $23.27M | $25.16M |
| Cash at Beginning of Period | $422.76M | $239.62M | $270.39M | $230.78M | $241.18M | $189.21M | $49.27M | $85.26M | $120.86M | $388.88M | $262.73M | $284.31M | $297.16M | $310.00M | $154.87M | $43.73M | $19.69M | $23.27M | $25.16M | $27.33M |
| Operating Cash Flow | $-30.01M | $50.75M | $-49.13M | $-49.73M | $-41.37M | $-37.06M | $-42.43M | $-25.98M | $-35.31M | $-23.21M | $-29.79M | $-21.56M | $-13.17M | $-12.22M | $-13.41M | $-9.74M | $-5.94M | $-3.58M | $-1.89M | $-2.08M |
| Capital Expenditure | $-1.42M | $-55.72M | $-17.13M | $- | $-8.00K | $-3.04M | $-149.00K | $-26.00K | $- | $-4.00K | $-7.00K | $-15.00K | $8.00M | $- | $- | $-8.00M | $1.00K | $- | $-5.00K | $-88.00K |
| Free Cash Flow | $-31.43M | $-4.97M | $-66.25M | $-49.73M | $-41.38M | $-40.10M | $-42.58M | $-26.01M | $-35.31M | $-23.22M | $-29.79M | $-21.58M | $-5.17M | $-12.22M | $-13.41M | $-17.74M | $-5.94M | $-3.58M | $-1.89M | $-2.17M |
Day One Biopharmaceuticals Dividends
Explore Day One Biopharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Day One Biopharmaceuticals News
Read the latest news about Day One Biopharmaceuticals, including recent articles, headlines, and updates.
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Charles York - COO and CFO Conference Call Participants Andrea Newkirk - Goldman Sachs Tara Bancroft - TD Cowen Joe Catanzaro - Piper Sandler Alec Stranahan - Bank of America Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 193.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m.
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has significant upside potential, with Wall Street targeting a 190% increase. Strong financial position with $558.4M in cash and a cash runway of over 3 years significantly reducing the dilution risk.
Day One Biopharmaceuticals: Sales Figures In The Crosshairs
Day One Biopharmaceuticals' key asset, tovorafenib, shows promise in treating pediatric low-grade glioma, with ongoing phase 3 trials aiming to expand its use. DAWN's financial health is strong, with $422.8 million in cash and equivalents, ensuring sustainability for over two years despite a net loss excluding licensing revenue. The company's deep cash reserves and promising pipeline, including the new DAY301 agent, provide a solid foundation for future growth and drug development.
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time.
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D.
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 3:00 p.m. EST.
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Samuel Blackman - Co-Founder and Head, R&D Charles York - COO and CFO Conference Call Participants Anupam Rama - JPMorgan Joe Catanzaro - Piper Sandler Andrea Newkirk - Goldman Sachs Soumit Roy - Jones Research Alec Stranahan - Bank of America Ami Fadia - Needham & Company Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals' Third Quarter of 2024 Financial and Operating Results Conference Call.
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Achieved $20.1 million in OJEMDA TM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, October 30, 4:30 p.m. Eastern Time BRISBANE, Calif.
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 140.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Wednesday, October 30, 2024 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2024.
Day One Announces Oversubscribed $175.0 Million Private Placement
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it has entered into a securities purchase agreement for an oversubscribed private placement of its securities for gross proceeds of approximately $175.0 million, before deducting placement agent fees and other expenses.
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain cancer, i and any future indications developed by Day One.
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024
Day One Announces Sale of Priority Review Voucher for $108 Million
BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it sold its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration (FDA) accelerated approval of OJEMDA™ (tovorafenib).
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DAWN.